A team of international researchers led by Professor Johan Jakobsson at Lund University has secured a 52 million SEK grant from the Aligning Science ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...